Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: A case-control study

Transplant Infectious Disease

Volumn 16, Issue 5, 2014, Pages 775-782

  Simkins, J ^a   Muggia, V ^a   Cohen, H W ^a   Minamoto, G Y ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Carbapenem resistance; Kidney transplantation; Klebsiella pneumoniae infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CALCINEURIN INHIBITOR; CARBAPENEM; CEFEPIME; CEPHALOSPORIN; COTRIMOXAZOLE; FOSFOMYCIN; HYPERTENSIVE AGENT; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; MONOBACTAM DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYMYXIN B; QUINOLONE DERIVATIVE; RAPAMYCIN; THYMOCYTE ANTIBODY; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACUTE GRAFT REJECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE INFECTION; CARBAPENEM SENSITIVE KLEBSIELLA PNEUMONIAE INFECTION; CASE CONTROL STUDY; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEBRIDEMENT; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANT RECIPIENT; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SURGICAL MORTALITY; SURVIVOR; URETEROPELVIC JUNCTION OBSTRUCTION; URINARY TRACT OBSTRUCTION; WOUND INFECTION; ADVERSE EFFECTS; AGED; DRUG EFFECTS; HOSPITALIZATION; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MORTALITY; SURVIVAL RATE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALIZATION; HUMANS; KIDNEY TRANSPLANTATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84907951209     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12276     Document Type: Article

References (27)

1. Van Duin D, van Delden C. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 31-41.
2. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis 2009; 9 (4): 228-236.
3. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65 (6): 1119-1125.
4. Centers for Disease Control and Prevention (CDC). Healthcare-associated infections. Tracking Carbapenem-resistant Enterobacteriaceae; September 2012. Available at http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html (Accessed February 12, 2014).
5. Srinivasan A, Patel JB. Klebsiella pneumonia carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008; 29 (12): 1107-1109.
6. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165 (12): 1430-1435.
7. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005; 49 (7): 3018-3020.
8. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52 (3): 1028-1033.
9. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29 (12): 1099-1106.
10. Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010; 31 (12): 1250-1256.
11. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumonia carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 2012; 14 (2): 198-205.
12. Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 2012; 18 (4): 468-474.
13. Centers for Disease Control and Prevention (CDC). CDC/NHSN Surveillance Definitions for Specific Types of Infections; January 2014. Available at http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf (Accessed February 12, 2014).
14. Goldfarb D, Harvey SB, Jessamine K, Jessamine P, Tove B, Desjardins M. Detection of plasmid-mediated KPC-producing Klebsiella pneumoniae in Ottawa, Canada: evidence of intrahospital transmission. J Clin Microbiol 2009; 47 (6): 1920-1922.
15. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53 (1): 60-67.
16. Ariza-Heredia EJ, Patel R, Blumberg EA, et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis 2012; 14 (3): 229-236.
17. Parasuraman R, Julian K. Urinary tract infections in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 327-336.
18. Bates D, Parkins M, Hellweg R, Gibson K, Bugar JM. Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review. Can J Hosp Pharm 2012; 65 (3): 209-215.
19. Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother 2007; 19 (6): 753-754.
20. Nix DE, Matthias KR. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother 2010; 65 (6): 1311-1312.
21. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; 17 (Suppl 1): 12-22.
22. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54 (12): 1699-1709.
23. Mathers AJ, Cox HL, Bonatti H, et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009; 11 (3): 257-265.
24. Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia Lymphoma 2013; 54 (4): 799-806.
25. Guerra G, Ilahe A, Ciancio G. Diabetes and kidney transplantation: past, present, and future. Curr Diab Rep 2012; 12 (5): 597-603.
26. Demirci MS, Yilmaz F, Ertilav M, et al. Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant 2010; 24 (5): 170-177.
27. Saleem TF, Cunningham KE, Hollenbeak CS, Alfrey EJ, Gabbay RA. Development of diabetes mellitus post-renal transplantation is associated with poor short-term clinical outcomes. Transplant Proc 2003; 35 (8): 2916-2918.